title: Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Kluger
authors.forename: Céline
authors.initials: C
authors.lastname: Girard
authors.forename: Bernard
authors.initials: B
authors.lastname: Guillot
authors.forename: Didier
authors.initials: D
authors.lastname: Bessis
mesh_terms: D000208:Acute Disease; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003879:Dermatologic Agents / Q000009:adverse effects*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D000069285:Infliximab; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068800:Etanercept